Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Novel Targeted Therapies in Brain Tumors
share announcement

Novel Targeted Therapies in Brain Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 4825

Special Issue Editors

Prof. Dr. Maria Caffo

E-Mail Website
Guest Editor
Unit of Neurosurgery, Department of Biomorphology and Dental Sciences, and Morphofunctional Imaging, University of Messina, AOU “G. Martino”, Messina, Italy
Interests: neurooncology; brain tumors; glioma; target-therapy; meningioma; neurosurgery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Emanuela Esposito

E-Mail Website
Guest Editor
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98122 Messina, Italy
Interests: neuroinflammation; neuromodulation; astrocytes; spinal cord injury; brain trauma; cytokines; neurodegenerative disorders; brain tumors
Special Issues, Collections and Topics in MDPI journals
Dr. Paola Gaviani

E-Mail Website
Guest Editor
Neuro Oncology Unit, Neuro Oncology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy
Interests: neurooncology; brain tumors; gliomas; systemic and target chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain tumors are a heterogeneous group of neoplasms, the most common being gliomas, that differ in their spectrum of behavior, from those which are relatively benign to the most malignant, glioblastoma multiforme. Due to their micro-environment within the central nervous system, and due to the presence of blood–brain barrier, blood–cerebrospinal fluid barrier, and blood–tumor barrier, brain tumors are well isolated from systemic circulation. For this reason, systemic therapy has been mostly unsuccessful. However, brain tumors no longer carry the same prognosis as they did some years ago. Improvements in surgery can related with this view as well as for the other innovative therapies combined with surgery.

The possibility of targeted therapies, which spare normal tissue and destroy tumor cells, is changing the field of Neuro-Oncology, with significant impact on the treatment of malignant brain tumors in the near future. These treatments do their effect principally with two mechanisms. One group is monoclonal antibodies which block receptors of the cell surface, deliver antineoplastic agents or facilitate the immune response. A second group of agents are small molecules which enter the cells and interrupt signaling pathways that are important for neoplasms growth. Therefore, comprehensive approaches are needed to achieve maximally from promising targeted therapies. Common methods used for crucial evaluation of targeted therapies for brain tumors involve: novel methods for targeted delivery of chemotherapy and strategies for delivery through BBB and blood-tumor barriers; a better understanding of personalized/precision medicine approaches to therapy in clinical trials and translation into practice of neurosurgery and neuro-oncology, suggests optimism for the future management of brain tumors.

We are pleased to invite you collaborate and work with us to send your article, research, trials or review on these above mentioned subjects.

This Special Issue aims to focus about novel aspects of precision medicine in Neuro-oncology, targeted and immunotherapy, clinical research specific open clinical trials and comprensive  reviews.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Prof. Dr. Maria Caffo
Prof. Dr. Emanuela Esposito
Dr. Paola Gaviani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision-medicine
  • targeted-therapy
  • brain tumors
  • immunotherapy
  • glioma
  • meningioma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3604 KiB  
Article
Enhancing the Efficacy of Radiation Therapy by Photochemical Internalization of Fibrin-Hydrogel-Delivered Bleomycin
by Sophia Renee Laurel, Keya Gupta, Jane Nguyen, Akhil Chandekar, Justin Le, Kristian Berg and Henry Hirschberg
Cancers 2024, 16(23), 4029; https://doi.org/10.3390/cancers16234029 - 30 Nov 2024
Viewed by 1054
Abstract
Background/Objectives: Although the use of radiation-sensitizing agents has been shown to enhance the effect of radiation on tumor cells, the blood–brain barrier (BBB) impedes these agents from reaching brain tumor sites when provided systemically. Localized methods of sensitizer delivery, utilizing hydrogels, have the [...] Read more.
Background/Objectives: Although the use of radiation-sensitizing agents has been shown to enhance the effect of radiation on tumor cells, the blood–brain barrier (BBB) impedes these agents from reaching brain tumor sites when provided systemically. Localized methods of sensitizer delivery, utilizing hydrogels, have the potential to bypass the blood–brain barrier. This study examined the ability of photochemical internalization (PCI) of hydrogel-released bleomycin to enhance the growth-inhibiting effects of radiation on multi-cell glioma spheroids in vitro. Methods: Loaded fibrin hydrogel layers were created by combining thrombin, fibrinogen, and bleomycin (BLM). Supernatants from these layers were collected, combined with photosensitizer, and added to F98 glioma spheroid cultures. Following light (PCI) and radiation treatment, at increasing dosages, spheroid growth was monitored for 14 days. Results: PCI of released BLM significantly reduced the radiation dose required to achieve equivalent efficacy compared to radiation or BLM + RT alone. Both immediate and delayed RT delivery post-BLM-PCI resulted in similar degrees of growth inhibition. Conclusions: Non-degraded BLM was released from the fibrin hydrogel. PCI of BLM synergistically increased the growth-inhibiting effects of radiation treatment compared to radiation and BLM, as well as radiation acting as a single treatment. Full article
(This article belongs to the Special Issue Novel Targeted Therapies in Brain Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 333 KiB  
Review
Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications
by Gerardo Caruso, Rosamaria Ferrarotto, Antonello Curcio, Luisa Metro, Francesco Pasqualetti, Paola Gaviani, Valeria Barresi, Filippo Flavio Angileri and Maria Caffo
Cancers 2023, 15(18), 4521; https://doi.org/10.3390/cancers15184521 - 12 Sep 2023
Cited by 8 | Viewed by 2777
Abstract
Meningiomas are the most frequent histotypes of tumors of the central nervous system. Their incidence is approximately 35% of all primary brain tumors. Although they have the status of benign lesions, meningiomas are often associated with a decreased quality of life due to [...] Read more.
Meningiomas are the most frequent histotypes of tumors of the central nervous system. Their incidence is approximately 35% of all primary brain tumors. Although they have the status of benign lesions, meningiomas are often associated with a decreased quality of life due to focal neurological deficits that may be related. The optimal treatment is total resection. Histological grading is the most important prognostic factor. Recently, molecular alterations have been identified that are specifically related to particular phenotypes and, probably, are also responsible for grading, site, and prognostic trend. Meningiomas recur in 10–25% of cases. In these cases, and in patients with atypical or anaplastic meningiomas, the methods of approach are relatively insufficient. To date, data on the molecular biology, genetics, and epigenetics of meningiomas are insufficient. To achieve an optimal treatment strategy, it is necessary to identify the mechanisms that regulate tumor formation and progression. Combination therapies affecting multiple molecular targets are currently opening up and have significant promise as adjuvant therapeutic options. We review the most recent literature to identify studies investigating recent therapeutic treatments recently used for meningiomas. Full article
(This article belongs to the Special Issue Novel Targeted Therapies in Brain Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop